{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Serosal Fluid', 'Any pericardial, pleural, and/or ascitic fluid collected as part of routine care (e.g., as part', 'of a therapeutic thoracentesis, pericardiocentesis, or paracentesis) will be procured for', 'possible PK, pharmacodynamic, and/or biomarker testing. See the laboratory manual for', 'additional details.', 'Pharmacogenetic Samples', 'A whole blood sample for DNA isolation will be collected on Cycle 1 Day 1 (pre-', 'infusion) and End of Treatment Visit from each subject. Pharmacogenetic collection', 'should occur unless precluded by local or national regulations or policies.', 'Samples will be shipped frozen to AbbVie or a designated laboratory for DNA extraction', 'and long-term storage. Instructions for the preparation and shipment of the', 'pharmacogenetic exploratory research samples will be provided in a laboratory manual.', 'Optional Exploratory Research Samples', 'Subjects will have the option to provide samples for exploratory research. Subjects may', 'still participate in the main study even if they decide not to participate in this optional', 'exploratory research.', 'AbbVie (or people or companies working with AbbVie) will store the exploratory', 'research samples in a secure storage space with adequate measures to protect', 'confidentiality. The samples will be retained while research on rovalpituzumab tesirine', '(or drugs of this class) or this disease and related conditions continues, but for no longer', 'than 20 years after study completion. The procedure for obtaining and documenting', 'informed consent for exploratory research samples is discussed in Section 9.3.', 'Tumor Material at the Time of Disease Progression', 'An optional tumor material collection by biopsy procedure may be obtained at the time of', 'disease progression, from subjects who consent to undergo biopsy procedure to better', '57']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'understand mechanisms of resistance and expression of DLL3. Other nucleic acid or', 'protein based biomarkers related to the response to rovalpituzumab tesirine and SCLC', 'biology may be assessed.', 'Samples will be shipped to AbbVie or a designated laboratory for long-term storage.', 'Instructions for the preparation and shipment of the biomarker exploratory research', 'samples will be provided in a laboratory manual.', '5.3.2', 'Drug Concentration Measurements', '5.3.2.1', 'Collection of Samples for Analysis', 'Approximately 6 mL of blood will be collected by venipuncture for pharmacokinetic', '(PK), Anti-therapeutic antibody (ATA), and neutralizing antibodies (nAb) testing as', 'indicated in Appendix C, Study Activities. Two samples will be collected at each', 'treatment cycle. The pre-infusion sample will be collected prior to dosing on Day 1', '(-3 days window is allowed) and the second sample will be collected within 60 minutes', 'post-infusion. Only one collection will be required at the Non-Treatment Cycle visit and', 'EOT visit. Blood will be processed to serum and three aliquots generated, each', 'containing approximately 0.8 mL of serum.', 'The date and time of each sample collected will be recorded to the nearest minute.', '5.3.2.2', 'Handling/Processing of Samples', 'Specific instructions for collection of blood/serum samples and subsequent preparation', 'and storage of the samples for the assays will be provided by the central laboratory,', 'AbbVie, or its designee.', '5.3.2.3', 'Disposition of Samples', 'The frozen serum samples for the rovalpituzumab tesirine ADC, rovalpituzumab tesirine', 'ADC ATA, and neutralizing antibodies (nAb) assays will be packed in dry ice sufficient', 'to last during transportation and shipped from the study site to the central laboratory.', '58']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'An inventory of the included samples will accompany the package and an electronic copy', 'of the manifests (including subject number, study day, the time of sample collection and', 'barcode) will be sent to the contact person at gprd_lupet@abbvie.com.', '5.3.2.4', 'Measurement Methods', 'Serum concentrations of rovalpituzumab tesirine ADC and relative titers of', 'rovalpituzumab tesirine ADC ATA will be determined using validated methods. Any', 'additional related analytes may be analyzed using non-validated methods. Serum samples', 'collected for the PK, ATA and nAb analysis may be used for future assay development or', 'validation activities. Rovalpituzumab tesirine ADC nAb samples upon request may be', 'used for the analysis of neutralizing anti-drug antibodies in a validated assay.', '5.3.3', 'Efficacy Variables', '5.3.3.1', 'Definition of Disease Progression', 'Disease progression will be defined as radiographic progression of disease by RECIST', 'version 1.1. Refer to Appendix G, Response Evaluation Criteria for Solid Tumors', '(RECIST) version 1.1 for Tumor Response. 12 Effusions (pleural, pericardial, etc.) will', 'contribute to disease response assessment only if confirmed malignant by cytology or', 'otherwise clearly disease-related; if disease progression is suspected solely based on the', 'appearance of new or increase of existing effusions, confirmation of malignant nature of', 'such effusions is strongly recommended prior to making the decision on treatment', 'discontinuation due to known adverse event profile of rovalpituzumab tesirine. If', 'collected, effusion fluid must be tested centrally and/or locally for cytology if disease', 'progression due to appearance/worsening of effusion is suspected.', '5.3.3.2', 'Primary Variables', 'The primary endpoints are progression-free survival (PFS) determined by a Central', 'Radiographic Assessment Committee (CRAC) per RECIST V. 1.1 and overall survival', '(OS) in DLL3high population.', '59']\n\n###\n\n", "completion": "END"}